Bao Yang, Han Xiao, Liu Da, Tan Zhaolin, Deng Yongzhi
Department of Endosecretory Metabolic Diseases, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, China.
School of Pharmacy, Changchun University of Chinese Medicine, Changchun, Jilin, China.
Front Immunol. 2022 Dec 23;13:1072376. doi: 10.3389/fimmu.2022.1072376. eCollection 2022.
Metabolic syndrome mainly includes obesity, type 2 diabetes (T2DM), alcoholic fatty liver (NAFLD) and cardiovascular diseases. According to the ancient experience philosophy of Yin-Yang, monarch-minister compatibility of traditional Chinese medicine, prescription is given to treat diseases, which has the advantages of small toxic and side effects and quick effect. However, due to the diversity of traditional Chinese medicine ingredients and doubts about the treatment theory of traditional Chinese medicine, the mechanism of traditional Chinese medicine is still in doubt. Gastrointestinal tract is an important part of human environment, and participates in the occurrence and development of diseases. In recent years, more and more TCM researches have made intestinal microbiome a new frontier for understanding and treating diseases. Clinically, nonalcoholic fatty liver disease (NAFLD) and diabetes mellitus (DM) often co-occur. Our aim is to explain the mechanism of interaction between gastrointestinal microbiome and traditional Chinese medicine (TCM) or traditional Chinese medicine formula to treat DM and NAFLD. Traditional Chinese medicine may treat these two diseases by influencing the composition of intestinal microorganisms, regulating the metabolism of intestinal microorganisms and transforming Chinese medicinal compounds.
代谢综合征主要包括肥胖、2型糖尿病(T2DM)、非酒精性脂肪性肝病(NAFLD)和心血管疾病。根据中医阴阳的古老经验哲学、君臣配伍原则组方治病,具有毒副作用小、疗效快等优点。然而,由于中药成分的多样性以及对中医治疗理论的质疑,中药的作用机制仍存在疑问。胃肠道是人体环境的重要组成部分,参与疾病的发生和发展。近年来,越来越多的中医研究将肠道微生物群作为理解和治疗疾病的新前沿。临床上,非酒精性脂肪性肝病(NAFLD)和糖尿病(DM)常同时出现。我们的目的是解释胃肠道微生物群与中药或中药方剂相互作用治疗DM和NAFLD的机制。中药可能通过影响肠道微生物的组成、调节肠道微生物的代谢以及转化中药化合物来治疗这两种疾病。